A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer

Antonio Cubillo, Ovidio Hernando-Requejo, Elena García-García, Jesús Rodriguez-Pascual, Emilio De Vicente, Pía Morelli, Carmen Rubio, Fernando López-Ríos, Avertano Muro, Ulpiano López, Susana Prados, Yolanda Quijano, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the feasibility of personalizing chemotherapy in patients with rectal cancer. Methods: Patients with cT3 or cN1 and cM0 rectal cancer were eligible. A set of 6 molecular markers including KRAS, BRAF, and PI3K mutations and expression of topoisomerase-1 (Topo-1), ERCC-1, and thymidylate synthase (TS) using immunohistochemistry were performed in a tumor biopsy. All patients were treated with capecitabine 625 to 825 mg/m 2/12 h M-F in combination with either irinotecan or oxaliplatin based on Topo-1 and ERCC-1 expression plus either bevacizumab or cetuximab based on the mutation status. All patients received intensity-modulated radiation therapy. A surgery was performed 6 to 8 weeks after the treatment. Results: Fifteen patients (94%) had T3 tumor and 10 (62%) N+ disease of 16 patients enrolled. In all patients, the full set of markers was analyzed within 10 days. Seven patients had K-ras mutation, and 4, 5, and 10 expressed Topo-1, ERRC-1 and TS, respectively. All patients had wildtype BRAF and PI3K tumors. The median time from obtaining informed consent to the treatment period was 18 days and all patients completed the chemoradiation treatment. Fifty percent achieved a complete pathologic response to treatment. Four patients (25%) developed grade 3 proctitis or diarrhea. There were no relevant surgical complications. Sixty-nine percent of the patients received adjuvant XELOX. Conclusions: The individualization of neoadjuvant chemotherapy in patients with rectal cancer is feasible and leads to a high rate of pathologic response.

Original languageEnglish (US)
Pages (from-to)117-121
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume37
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Intensity-Modulated Radiotherapy
Rectal Neoplasms
Prospective Studies
Drug Therapy
Thymidylate Synthase
oxaliplatin
irinotecan
Phosphatidylinositol 3-Kinases
Mutation
Proctitis
Neoplasms
Therapeutics
Informed Consent
Diarrhea

Keywords

  • Molecular targets
  • Personalized treatment
  • Rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. / Cubillo, Antonio; Hernando-Requejo, Ovidio; García-García, Elena; Rodriguez-Pascual, Jesús; De Vicente, Emilio; Morelli, Pía; Rubio, Carmen; López-Ríos, Fernando; Muro, Avertano; López, Ulpiano; Prados, Susana; Quijano, Yolanda; Hidalgo, Manuel.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 37, No. 2, 2014, p. 117-121.

Research output: Contribution to journalArticle

Cubillo, A, Hernando-Requejo, O, García-García, E, Rodriguez-Pascual, J, De Vicente, E, Morelli, P, Rubio, C, López-Ríos, F, Muro, A, López, U, Prados, S, Quijano, Y & Hidalgo, M 2014, 'A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 37, no. 2, pp. 117-121. https://doi.org/10.1097/COC.0b013e31826e0703
Cubillo, Antonio ; Hernando-Requejo, Ovidio ; García-García, Elena ; Rodriguez-Pascual, Jesús ; De Vicente, Emilio ; Morelli, Pía ; Rubio, Carmen ; López-Ríos, Fernando ; Muro, Avertano ; López, Ulpiano ; Prados, Susana ; Quijano, Yolanda ; Hidalgo, Manuel. / A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2014 ; Vol. 37, No. 2. pp. 117-121.
@article{e502605b507f412db5c7d7fe45970a9c,
title = "A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer",
abstract = "Purpose: To investigate the feasibility of personalizing chemotherapy in patients with rectal cancer. Methods: Patients with cT3 or cN1 and cM0 rectal cancer were eligible. A set of 6 molecular markers including KRAS, BRAF, and PI3K mutations and expression of topoisomerase-1 (Topo-1), ERCC-1, and thymidylate synthase (TS) using immunohistochemistry were performed in a tumor biopsy. All patients were treated with capecitabine 625 to 825 mg/m 2/12 h M-F in combination with either irinotecan or oxaliplatin based on Topo-1 and ERCC-1 expression plus either bevacizumab or cetuximab based on the mutation status. All patients received intensity-modulated radiation therapy. A surgery was performed 6 to 8 weeks after the treatment. Results: Fifteen patients (94{\%}) had T3 tumor and 10 (62{\%}) N+ disease of 16 patients enrolled. In all patients, the full set of markers was analyzed within 10 days. Seven patients had K-ras mutation, and 4, 5, and 10 expressed Topo-1, ERRC-1 and TS, respectively. All patients had wildtype BRAF and PI3K tumors. The median time from obtaining informed consent to the treatment period was 18 days and all patients completed the chemoradiation treatment. Fifty percent achieved a complete pathologic response to treatment. Four patients (25{\%}) developed grade 3 proctitis or diarrhea. There were no relevant surgical complications. Sixty-nine percent of the patients received adjuvant XELOX. Conclusions: The individualization of neoadjuvant chemotherapy in patients with rectal cancer is feasible and leads to a high rate of pathologic response.",
keywords = "Molecular targets, Personalized treatment, Rectal cancer",
author = "Antonio Cubillo and Ovidio Hernando-Requejo and Elena Garc{\'i}a-Garc{\'i}a and Jes{\'u}s Rodriguez-Pascual and {De Vicente}, Emilio and P{\'i}a Morelli and Carmen Rubio and Fernando L{\'o}pez-R{\'i}os and Avertano Muro and Ulpiano L{\'o}pez and Susana Prados and Yolanda Quijano and Manuel Hidalgo",
year = "2014",
doi = "10.1097/COC.0b013e31826e0703",
language = "English (US)",
volume = "37",
pages = "117--121",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer

AU - Cubillo, Antonio

AU - Hernando-Requejo, Ovidio

AU - García-García, Elena

AU - Rodriguez-Pascual, Jesús

AU - De Vicente, Emilio

AU - Morelli, Pía

AU - Rubio, Carmen

AU - López-Ríos, Fernando

AU - Muro, Avertano

AU - López, Ulpiano

AU - Prados, Susana

AU - Quijano, Yolanda

AU - Hidalgo, Manuel

PY - 2014

Y1 - 2014

N2 - Purpose: To investigate the feasibility of personalizing chemotherapy in patients with rectal cancer. Methods: Patients with cT3 or cN1 and cM0 rectal cancer were eligible. A set of 6 molecular markers including KRAS, BRAF, and PI3K mutations and expression of topoisomerase-1 (Topo-1), ERCC-1, and thymidylate synthase (TS) using immunohistochemistry were performed in a tumor biopsy. All patients were treated with capecitabine 625 to 825 mg/m 2/12 h M-F in combination with either irinotecan or oxaliplatin based on Topo-1 and ERCC-1 expression plus either bevacizumab or cetuximab based on the mutation status. All patients received intensity-modulated radiation therapy. A surgery was performed 6 to 8 weeks after the treatment. Results: Fifteen patients (94%) had T3 tumor and 10 (62%) N+ disease of 16 patients enrolled. In all patients, the full set of markers was analyzed within 10 days. Seven patients had K-ras mutation, and 4, 5, and 10 expressed Topo-1, ERRC-1 and TS, respectively. All patients had wildtype BRAF and PI3K tumors. The median time from obtaining informed consent to the treatment period was 18 days and all patients completed the chemoradiation treatment. Fifty percent achieved a complete pathologic response to treatment. Four patients (25%) developed grade 3 proctitis or diarrhea. There were no relevant surgical complications. Sixty-nine percent of the patients received adjuvant XELOX. Conclusions: The individualization of neoadjuvant chemotherapy in patients with rectal cancer is feasible and leads to a high rate of pathologic response.

AB - Purpose: To investigate the feasibility of personalizing chemotherapy in patients with rectal cancer. Methods: Patients with cT3 or cN1 and cM0 rectal cancer were eligible. A set of 6 molecular markers including KRAS, BRAF, and PI3K mutations and expression of topoisomerase-1 (Topo-1), ERCC-1, and thymidylate synthase (TS) using immunohistochemistry were performed in a tumor biopsy. All patients were treated with capecitabine 625 to 825 mg/m 2/12 h M-F in combination with either irinotecan or oxaliplatin based on Topo-1 and ERCC-1 expression plus either bevacizumab or cetuximab based on the mutation status. All patients received intensity-modulated radiation therapy. A surgery was performed 6 to 8 weeks after the treatment. Results: Fifteen patients (94%) had T3 tumor and 10 (62%) N+ disease of 16 patients enrolled. In all patients, the full set of markers was analyzed within 10 days. Seven patients had K-ras mutation, and 4, 5, and 10 expressed Topo-1, ERRC-1 and TS, respectively. All patients had wildtype BRAF and PI3K tumors. The median time from obtaining informed consent to the treatment period was 18 days and all patients completed the chemoradiation treatment. Fifty percent achieved a complete pathologic response to treatment. Four patients (25%) developed grade 3 proctitis or diarrhea. There were no relevant surgical complications. Sixty-nine percent of the patients received adjuvant XELOX. Conclusions: The individualization of neoadjuvant chemotherapy in patients with rectal cancer is feasible and leads to a high rate of pathologic response.

KW - Molecular targets

KW - Personalized treatment

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84900473337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900473337&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31826e0703

DO - 10.1097/COC.0b013e31826e0703

M3 - Article

C2 - 23211222

AN - SCOPUS:84900473337

VL - 37

SP - 117

EP - 121

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -